Compare AstraZeneca plc (AZN) vs iShares JPMorgan USD Emerging Markets Bond ETF (EMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs iShares JPMorgan USD Emerging Markets Bond ETF — how do they compare? AstraZeneca plc trades at $168.36 (market cap $253.13B), while iShares JPMorgan USD Emerging Markets Bond ETF trades at $95.75. The key difference: AstraZeneca plc pays a 1.92% dividend while iShares JPMorgan USD Emerging Markets Bond ETF pays none, and iShares JPMorgan USD Emerging Markets Bond ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | EMB | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Fixed Income |
52-Week High | $209.48 | $97.74 |
52-Week Low | $137.44 | $91.52 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
EMB trades at $95.38, down 0.64% on the day, with a bearish technical signal from moving averages and oscillators. The stock shows oversold conditions with a 6-day RSI at 29.09, while recent corporate actions include scheduled dividends for mid-2026. News coverage highlights emerging market bond risks and Federal Reserve policy impacts on similar ETFs.
The outlook remains cautious due to technical weakness and macro risks in emerging markets. Investment opportunity lies in potential oversold rebound, but risks include sovereign default exposure and interest rate sensitivity. Investor sentiment is mixed amid global fixed income volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →
